Grass Sensitisation and Allergic Rhinitis in Thai Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Mahidol University
Sponsor:
Collaborator:
National Research Council of Thailand
Information provided by (Responsible Party):
Punchama Pacharn, Mahidol University
ClinicalTrials.gov Identifier:
NCT01686022
First received: September 12, 2012
Last updated: April 27, 2013
Last verified: April 2013
  Purpose

Allergic rhinitis patients are the patients who have nasal symptoms when triggered by indoor or outdoor allergens. Outdoor allergen can be divided into grass, tree, or weed. The type of grass or weed are different in various part of the world. The allergens from grass and weed has never been studied in Thailand. This study will find the major allergen from Bermuda grass, Johnson grass, Para grass, sedge, and ragweed, which are very common in Thailand. In addition, the investigators will study about the cross-reactivity among these group of allergen.


Condition Intervention
Allergy to Grass Pollen
Allergic Rhinitis Due to Weed Pollens
Other: Immunoblot

Study Type: Observational
Official Title: The Study of Allergens From Grass and Weed Which Are Causes of Allergic Rhinitis in Thai Patients

Resource links provided by NLM:


Further study details as provided by Mahidol University:

Biospecimen Retention:   Samples Without DNA

Serum


Estimated Enrollment: 185
Study Start Date: October 2012
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pollen Allergy
Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
Other: Immunoblot
serum specific IgE binds to grass extract by immunoblot

Detailed Description:

To find the major allergen of grass and weed, the serum of patients will be used to bind with the allergen extract by immunoblot study.

The ELISA-inhibition will be used to study about cross-reactivity among various kinds of grass and weed.

  Eligibility

Ages Eligible for Study:   10 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Allergy Clinic

Criteria

Inclusion Criteria:

  • Allergic rhinitis patients age 10-50 years old
  • Control: healthy volunteer age 18-50 years old

Exclusion Criteria:

  • Chronic illness such as cardiovascular diseases, liver diseases
  • History of anaphylaxis
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01686022

Contacts
Contact: Punchama Pacharn, MD 6624197000 ext 5670 punchama@gmail.com
Contact: Chaweewan Bunnag, MD 6624197000 ext 8040 sicbg@mahidol.ac.th

Locations
Thailand
Siriraj Hospital Recruiting
Bangkoknoi, Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
National Research Council of Thailand
Investigators
Principal Investigator: Punchama Pacharn, MD Mahidol University
  More Information

No publications provided

Responsible Party: Punchama Pacharn, Principal investigator, Mahidol University
ClinicalTrials.gov Identifier: NCT01686022     History of Changes
Other Study ID Numbers: NRCT_G04
Study First Received: September 12, 2012
Last Updated: April 27, 2013
Health Authority: Thailand: Ethical Committee

Keywords provided by Mahidol University:
Grass
Major allergen
cross-reactivity

Additional relevant MeSH terms:
Rhinitis
Hypersensitivity
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Immune System Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate

ClinicalTrials.gov processed this record on August 27, 2014